The 18F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Can-cer J Clin 2015; 65(1): 5−29.
Institute of Public Health of Serbia “Dr Milan Jovanović Ba-tut”. Cancer incidence and mortality in central Serbia 2012. 2015. [cited 2015 Aug 17]. Available from: http://www.batut.org.rs/index.php.
Cancer registry data of Oncology Institute of Vojvodina [un-published database]. Sremska Kamenica, Serbia: Oncology In-stitute of Vojvodina; 2010.
Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 2003; 44(7): 1044−50.
Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 2010; 31(6): 496−505.
Eubank WB, Mankoff DA, Schmiedl UP, Winter TC, Fisher ER, Olshen AB, et al.. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. AJR Am J Roentgenol 1998; 171(4): 1103−10.
Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. In-itial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006; 33(3): 254−62.
Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, et al. Performance of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography and Integrated PET/CT in Restaged Breast Cancer Patients. Mol Imaging Bi-ol 2005; 7(5): 369−76.
Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009; 96(2): 166−70.
Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluo-rine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18(20): 3495−502.
Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42(1): 9−16.
Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymi-dine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998; 25(10): 1429−34.
Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol. Im-aging 2002; 29(10): 1317−23.
Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer meas-ured by positron emission tomography. J Clin Oncol 2002; 20(2): 379−87.
Buck AK, Schirrmeister H, Mattfeldt T, Reske SN. Biological cha-racterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004; 31(Suppl 1): S80−7.
Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer 2007; 14(3): 260−8.
Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med 2007; 48(8): 1266−72.
Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007; 73(11): 1151−7.
Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, et al. 18F-FDG PET of locally invasive breast cancer and associa-tion of estrogen receptor status with standardized uptake val-ue: microarray and immunohistochemical analysis. J Nucl Med 2010; 51(4): 543−50.
Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011; 38(3): 426−35.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyg-lucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008; 112(5): 995−1000.
Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer. Breast Can Res Treatment 2006; 98(3): 267−74.
Samson DJ, Flamm CR, Pisano ED, Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy. Acad Radiol 2002; 9(7): 773−83.
Danforth DN, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zu-jewski J, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002; 75(2): 135−46.
Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, et al. Breast cancer staging in a single session: Whole-body PET/CT mammography. J Nucl Med 2008; 49(8): 1215−22.
Murthy K, Aznar M, Thompson CJ, Loutfi A, Lisbona R, Gagnon JH. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 2000; 41(11): 1851−8.
Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman ER. De-tection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial expe-rience. Radiology 2005; 234(2): 527−34.
Berg WA, Weinberg IN, Narayanan D, Lobrano ME, Ross E, Amo-dei L, et al. High-Resolution Fluorodeoxyglucose Positron Emission Tomography with Compression ("Positron Emis-sion Mammography") is Highly Accurate in Depicting Primary Breast Cancer. Breast J 2006; 12(4): 309−23.
Levine EA, Freimanis RI, Perrier ND, Morton K, Lesko NM, Berg-man S, et al. Positron Emission Mammography: Initial Clinical Results. Ann Surg Oncol 2003; 10(1): 86−91.
Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. RadioGraphics 2007; 27(1): 215−29.
Berg WA, Madsen KS, Schilling K, Tartar M, Pisano ED, Larsen LH, et al. Breast cancer: Comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology 2011; 258(1): 59−72.
Litmanovich D, Gourevich K, Israel O, Gallimidi Z. Unexpected foci of 18F-FDG uptake in the breast detected by PET/CT: in-cidence and clinical significance. Eur J Nucl Med Mol Imaging 2009; 36(10): 1558−64.
Lyman GH. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. J Clin Oncol 2005; 23(30): 7703−20.
Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007; 18(3): 473−8.
Cooper KL, Harnan S, Meng Y, Ward SE, Fitzgerald P, Papaioannou D, et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol 2011; 37(3): 187−98.
Gil-Rendo A, Zornoza G, García-Velloso MJ, Regueira FM, Beorlegui C, Cervera M. Fluorodeoxyglucose positron emission tomogra-phy with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 2006; 93(6): 707−12.
Avril N, Dose J, Jänicke F, Ziegler S, Römer W, Weber W, et al. As-sessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl. Cancer Inst 1996; 88(17): 1204−9.
Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, PET Study Group . Prospective multicenter study of axillary nodal staging by po-sitron emission tomography in breast cancer: a report of the Staging Breast Cancer with PET Study Group. J Clin Oncol 2004; 22(2): 277−85.
Alberini J, Lerebours F, Wartski M, Fourme E, Le SE, Gontier E, et al. 18F-fluorodeoxyglucose positron emission tomogra-phy/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 2009; 115(21): 5038−47.
Groheux D, Moretti J, Baillet G, Espie M, Giacchetti S, Hindie E, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008; 71(3): 695−704.
Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C, et al. Additional value of PET-CT in staging of clin-ical stage IIB and III breast cancer. Breast J 2010; 16(6): 617−24.
Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez AA, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary da-ta. J Nucl Med 2009; 50(2): 231−8.
Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am 2007; 45(4): 669−76.
Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005; 32(11): 1253−8.
Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial expe-rience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004; 45(2): 272−8.
Aukema TS, Rutgers TE, Vogel WV, Teertstra HJ, Oldenburg HS, Vrancken PM, et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to con-ventional imaging techniques. Eur J Surg Oncol 2010; 36(4): 387−92.
Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other im-aging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol 2010; 136(7): 1007−22.
Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. A systematic review of positron emission to-mography (PET) and positron emission tomogra-phy/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 2010; 14(50): 1−103.
Piperkova E, Raphael B, Altinyay ME, Castellon I, Libes R, Sandella N, et al. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med 2007; 32(6): 429−34.
Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, et al. Impact of FDG PET on defining the extent of dis-ease and on the treatment of patients with recurrent or metas-tatic breast cancer. AJR Am J Roentgenol 2004; 183(2): 479−86.
Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast can-cer. Cancer 2006; 107(11): 2545−51.
Dirisamer A, Halpern BS, Flöry D, Wolf F, Beheshti M, Mayerhoefer ME, et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2010; 73(2): 294−9.
Grassetto G, Fornasiero A, Otello D, Bonciarelli G, Rossi E, Nashim-ben O, et al. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a mul-ticentre study. Eur J Radiol 2011; 80(3): 828−33.
Champion L, Brain E, Giraudet A, Le Stanc E, Wartski M, Edeline V, et al. Breast cancer recurrence diagnosis suspected on tu-mor marker rising: value of whole-body 18FDG-PET/CT im-aging and impact on patient management. Cancer 2011; 117(8): 1621−9.
Filippi V, Malamitsi J, Vlachou F, Laspas F, Georgiou E, Prassopoulos V, et al. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nucl Med Commun 2011; 32(2): 85−90.
Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nucl Med Commun 2012; 33(6): 591−6.
Baum RP, Przetak C. Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q J Nucl Med 2001; 45(3): 257−68.
Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohor-monotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11(11): 2101−11.
Avril N, Dose J, Jänicke F, Bense S, Ziegler S, Laubenbacher C, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14(6): 1848−57.
Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002; 95(4): 681−95.
van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19(22): 4224−37.
Jung S, Kim S, Nam B, Min SY, Lee SJ, Park C, et al. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 2010; 17(1): 247−53.
Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemothe-rapy in breast cancer. J Clin Oncol 2000; 18(8): 1689−95.
Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli M, Vennin P, Servent V, Fournier C, et al. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. Breast Cancer Res Treat 2012; 131(2): 517−25.
Park SH, Moon WK, Cho N, Chang JM, Im S, Park IA, et al. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoad-juvant chemotherapy in patients with breast cancer. Eur Radiol 2012; 22(1): 18−25.
Andrade WP, Lima EN, Osório CA, Socorro MM, Baiocchi G, Bi-tencourt AG, et al. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer. Eur J Surg On-col 2013; 39(12): 1358−63.
Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, et al. Early metabolic response using FDG PET/CT and molecular phe-notypes of breast cancer treated with neoadjuvant chemothe-rapy. BMC Cancer 2011; 11: 452.
Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006; 24(34): 5366−72.
Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemo-therapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002; 38(3): 375−9.
Kim S, Kim S, Lee ES, Ro J, Kang Sh. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Annals of oncology 2004; 15(9): 1352−7.
Chen X, Moore MO, Lehman CD, Mankoff DA, Lawton TJ, Peacock S, et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 2004; 11(10): 1115−24.
Cachin F, Prince H, Hogg A, Ware RE, Hicks RJ. Powerful prog-nostic stratification by [18F]fluorodeoxyglucose positron emis-sion tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006; 24(19): 3026−31.
Dittmann H, Jusufoska A, Dohmen BM, Smyczek-Gargya B, Fersis N, Pritzkow M, et al. 3'-Deoxy-3'-[(18)F]fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment. Nucl Med Biol 2009; 36(2): 163−9.
Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J, et al. 18F]-3'Deoxy-3'-fluorothymidine positron emission tomo-graphy and breast cancer response to docetaxel. Clin Cancer Res 2011; 17(24): 7664−72.
Lubberink M, Direcks W, Emmering J, Tinteren H, Hoekstra OS, Hoeven JJ, et al. Validity of simplified 3'-deoxy-3'-[18F]fluorothymidine uptake measures for monitoring re-sponse to chemotherapy in locally advanced breast cancer. Mol Imaging Biol 2012; 14(6): 777−82.
Tehrani OS, Shields AF. PET imaging of proliferation with py-rimidines. J Nucl Med 2013; 54(6): 903−12.
Peterson LM, Kurland BF, Link JM, Schubert EK, Stekhova S, Lin-den HM, et al. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol 2011; 38(7): 969−78.
Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibi-tors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 2011;17(14):4799-805. 17(14): 4799-805. PubMed PMID: 21750198
van Kruchten M, Glaudemans AW, Vries EF, Beets-Tan RG, Schröder CP, Dierckx RA, et al.. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med 2012; 53(2): 182−90.
Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Mankoff DA. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med 2011; 52(10): 1541−9.
Paquette M, Phoenix S, Ouellet R, Langlois R, Lier JE, Turcotte EE, et al. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model. Mol Imaging Biol 2013; 15(5): 625−32.
Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 2007; 96(1): 104−9.
Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011; 101(3): 369−75.
Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in ma-lignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10(7): 2245−52.